2023年:心血管疾病之年——新的和前瞻性降脂疗法之年。我们能在2024年将血脂异常变成一种罕见的疾病吗?

IF 3 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Archives of Medical Science Pub Date : 2023-11-02 DOI:10.5114/aoms/174743

Maciej Banach, Stanisław Surma, Peter P Toth

{"title":"2023年:心血管疾病之年——新的和前瞻性降脂疗法之年。我们能在2024年将血脂异常变成一种罕见的疾病吗?","authors":"Maciej Banach, Stanisław Surma, Peter P Toth","doi":"10.5114/aoms/174743","DOIUrl":null,"url":null,"abstract":"In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process of atherosclerosis, ASCVD and its complications, on the methods of lipid disorders diagnosis, prevention, and treatment. Nowadays, almost 4 million deaths per year are attributed to LDL-C, and even 2/3 of all CVD deaths to ASCVD, therefore hypothetically we should easily prevent few to several million of deaths with early diagnosis, and early and intensive non-pharmacological and pharmacological therapies. Moreover, lipidology is the area with the highest number of new and ongoing trials with new medications that have already appeared and will soon be available. Therefore, we have no doubt that year 2023 should be called the year of new and prospective LLTs.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"22 10","pages":"0"},"PeriodicalIF":3.0000,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?\",\"authors\":\"Maciej Banach, Stanisław Surma, Peter P Toth\",\"doi\":\"10.5114/aoms/174743\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process of atherosclerosis, ASCVD and its complications, on the methods of lipid disorders diagnosis, prevention, and treatment. Nowadays, almost 4 million deaths per year are attributed to LDL-C, and even 2/3 of all CVD deaths to ASCVD, therefore hypothetically we should easily prevent few to several million of deaths with early diagnosis, and early and intensive non-pharmacological and pharmacological therapies. Moreover, lipidology is the area with the highest number of new and ongoing trials with new medications that have already appeared and will soon be available. Therefore, we have no doubt that year 2023 should be called the year of new and prospective LLTs.\",\"PeriodicalId\":8278,\"journal\":{\"name\":\"Archives of Medical Science\",\"volume\":\"22 10\",\"pages\":\"0\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-11-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/aoms/174743\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/aoms/174743","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

到2023年，仍有75%的患者超过LDL-C目标，高胆固醇血症是最常见和监测最差的心血管疾病危险因素。考虑到我们对胆固醇在动脉粥样硬化、ASCVD及其并发症过程中的作用的了解，以及对脂质紊乱的诊断、预防和治疗方法的了解，这是如何可能的。如今，每年有近400万人死于LDL-C，甚至有2/3的CVD死亡是由ASCVD造成的，因此，假设我们应该通过早期诊断和早期强化的非药物和药物治疗，很容易预防少数到数百万人的死亡。此外，脂质学是一个新的和正在进行的新药试验数量最多的领域，这些新药已经出现，并且很快就会出现。因此，我们毫无疑问，2023年应该被称为新的和潜在的llt之年。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process of atherosclerosis, ASCVD and its complications, on the methods of lipid disorders diagnosis, prevention, and treatment. Nowadays, almost 4 million deaths per year are attributed to LDL-C, and even 2/3 of all CVD deaths to ASCVD, therefore hypothetically we should easily prevent few to several million of deaths with early diagnosis, and early and intensive non-pharmacological and pharmacological therapies. Moreover, lipidology is the area with the highest number of new and ongoing trials with new medications that have already appeared and will soon be available. Therefore, we have no doubt that year 2023 should be called the year of new and prospective LLTs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Archives of Medical Science 医学-医学：内科

CiteScore

4.90

自引率

7.90%

发文量

139

审稿时长

1.7 months

期刊介绍： Archives of Medical Science (AMS) publishes high quality original articles and reviews of recognized scientists that deal with all scientific medicine. AMS opens the possibilities for young, capable scientists. The journal would like to give them a chance to have a publication following matter-of-fact, professional review by outstanding, famous medical scientists. Thanks to that they will have an opportunity to present their study results and/or receive useful advice about the mistakes they have made so far. The second equally important aim is a presentation of review manuscripts of recognized scientists about the educational capacity, in order that young scientists, often at the beginning of their scientific carrier, could constantly deepen their medical knowledge and be up-to-date with current guidelines and trends in world-wide medicine. The fact that our educational articles are written by world-famous scientists determines their innovation and the highest quality.